Nanosphere to Present at the Jefferies 2013 Global

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Nanosphere to Present at the Jefferies 2013 Global Healthcare Conference

NORTHBROOK, IL--(Marketwired - Jun 3, 2013) -   Nanosphere, Inc., ( NASDAQ : NSPH ), a leader in the development and commercialization of advanced molecular diagnostics systems, today announced that an overview of the company's business and commercial strategy will be given by Nanosphere's President and Chief Executive Officer Michael McGarrity at the Jefferies 2013 Global Healthcare Conference, being held at the Grand Hyatt Hotel in New York City. The Company presentation is on Wednesday, June 5 at 2:00pm Eastern Time.

A live webcast of Nanosphere's presentation will be available at www.nanosphere.us .

About Nanosphere, Inc. Nanosphere develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene® System, for multiplexed infectious disease, genetic, and ultra-sensitive protein testing. This easy-to-use platform offers laboratories a convenient, simple, and cost-effective solution for highly sensitive nucleic acid and protein testing. Nanosphere is based in Northbrook, IL.

For additional information regarding Nanosphere's infectious disease products, please contact Nanosphere at IDtesting@nanosphere.us or visit www.nanosphere.us .

Except for historical information, the matters discussed in this press release are "forward-looking statements" and are subject to risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the following: (i) Nanosphere's ability to develop commercially viable products; (ii) Nanosphere's ability to achieve profitability; (iii) Nanosphere's ability to produce and market its products; (iv) Nanosphere's ability to obtain regulatory approval of its products; (v) Nanosphere's ability to protect its intellectual property; (vi) competition and alternative technologies; and (vii) Nanosphere's ability to obtain additional financing to support its operations. Additional risks are discussed in the Company's current filings with the Securities and Exchange Commission. Although the Company believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. The forward-looking statements are made as of the date of this press release, and we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact: Nanosphere, Inc. Roger Moody 847-400-9021 Chief Financial Officer rmoody@nanosphere.us LifeSci Advisors, LLC Michael Rice 646-597-6979 Founding Partner mrice@lifesciadvisors.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Waystar Sees Stellar Q1 2025 Results With Revenue Increase

Updated Category News Views 624

Waystar Reports Stellar Q1 2025 Financial Results In the latest announcement, Waystar Holding Corp. (NASDAQ: WAY) has highlighted significant achievements for the first quarter of 2025, showcasing robust financial progress and promising future guidance. The company achieved an impressive revenue growth rate of 14% year-over-year, reflecting its continuing success as a...

Continue Reading
Innovative Power MOSFET to Boost Efficiency in AI Server Tech

Updated Category News Views 180

Revolutionizing AI Server Power Solutions ROHM Semiconductor has taken a significant step in advancing the technology landscape with their latest power MOSFET, the RS7P200BM. This innovative component is crafted specifically for AI servers, functioning within a compact 5.0mm × 6.0mm package. The introduction of this 100V power MOSFET stems from the increasing demands for...

Continue Reading
Sarclisa Gains EU Approval for New Multiple Myeloma Treatment

Updated Category News Views 319

Sarclisa Approved in the EU for New Treatment of Multiple Myeloma Sarclisa has recently achieved a significant milestone by obtaining approval in the European Union as the first anti-CD38 therapy designed for use in combination with the standard-of-care regimen known as VRd, to treat adult patients with newly diagnosed multiple myeloma (NDMM) who are not eligible for...

Continue Reading
Lifecore Biomedical Investors: Navigate Legal Rights with Precision

Updated Category News Views 83

Your Rights as a Lifecore Investor If you’ve invested in Lifecore Biomedical, Inc., you're at a key juncture as you navigate the complexities of legal action stemming from potential corporate misconduct. Understanding your options is crucial during this time. Details on the Class Action The Portnoy Law Firm has officially announced a class action for Lifecore...

Continue Reading
Natural Grocers Crowned Top Organic Retailer in 2024 Contest

Updated Category News Views 237

Natural Grocers Leads the Way in Organic Retail Natural Grocers is proud to announce that it has been named "Best Natural Food Stores for 2024" in a contest hosted by Green Matters. This award is a significant achievement, highlighting the company’s dedication to offering premium natural and organic products. A Well-Deserved Honor This recognition resulted from a public...

Continue Reading